ArticleLancet regional health. Americas2027
Life expectancy among women and men with HIV after achieving sustained virologic suppression in the Bronx, New York: a clinical cohort study.
Article in Lancet regional health. Americas, 2027. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Whether female lifespan advantage is maintained among people with virologically suppressed HIV is unclear. Localized cohorts with demographically similar women and men may reveal associations obscured nationally. We estimated sex differences in life expectancy among people with HIV (PWH) in the Bronx, NY, after first achieving sustained virologic suppression. Methods: Among PWH receiving care in Montefiore Health System in the Bronx, NY who achieved sustained virologic suppression for ≥1 year (1997-2021), follow-up began at the end of the earliest qualifying window (index date) and ended at death or 2023. A Poisson model estimated mortality rate ratios by age, sex, race/ethnicity, HIV acquisition category, CD4+ T-cell count, and health insurance at the index date; age-specific mortality rates estimated remaining life-years for a 30-year-old using Chiang's life table method. Findings: PWH (n = 9999; 4075 [41%] women, 8392 [84%] Black or Hispanic) were followed for a median of 10.7 years; 2675 (27%) died. Men had 32% higher mortality risk than women (rate ratio: 1.32; 95% CI: 1.21-1.43). Compared to Black (non-Hispanic) PWH, Hispanic PWH had 19% lower mortality risk (RR: 0.81; 95% CI: 0.74-0.88), while those with White or other/unknown race/ethnicity had higher mortality risk. Among PWH with public insurance and CD4+ T-cell count ≥500 cells/μL, remaining life-years at age 30 were 45 and 41 for Hispanic women and men with heterosexual acquisition, 42 and 38 for Black women and men with heterosexual acquisition, and 44 and 41 for Hispanic and Black men with MSM acquisition. Interpretation: Women with HIV in the Bronx after sustained virologic suppression lived approximately 4 years longer than comparable men, approaching sex differences in the general population. Local, disaggregated population analyses may help clarify sex differences in longevity among PWH, thereby informing clinical and public health priorities. Funding: NIH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.